David Bonnema, MD
Interventional Cardiology · Muskegon, MINPI 1538245501
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 71.7% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $4,311 and has fallen 92.7% since, to $314 in 2025.
Across 255 payments — averaging $48.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Novartis$1K
- Abiomed$728
- Pfizer$251
- Abbott$214
- Boston Scientific$206
- plus $919 from 11 others
Across 5 payments — averaging $36,593 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$183K
What the payments were for
- Travel & lodging$6,19550%
- Food & beverage$6,24850%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 84 | $8,936 |
| Novartis | 83 | $1,217 |
| Abiomed | 12 | $728 |
| Pfizer | 15 | $251 |
| Abbott | 2 | $214 |
| Boston Scientific | 5 | $206 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $205 |
| Irhythm Technologies, Inc. | 10 | $202 |
| E.r. Squibb & Sons, L.L.C. | 9 | $151 |
| Novo Nordisk | 8 | $138 |
| AstraZeneca | 7 | $98 |
| Penumbra, Inc. | 1 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Heartflow, Inc. | 1 | $22 |
| Cordis US CORP. | 1 | $20 |
| Biotronik Inc. | 1 | $14 |
| Terumo Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$3,041
- EVERA MRI XT DR SURESCAN$1,178
- Impella$264
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$159
How this compares
$12,471 in reported general payments places this provider in the 65th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 127 | $140,765 |
| EntrestoSacubitril/Valsartan | 118 | $122,210 |
| Repatha SureclickEvolocumab | 36 | $45,383 |
| BrilintaTicagrelor | 32 | $32,481 |
| FarxigaDapagliflozin Propanediol | 13 | $13,654 |
| Metoprolol Succinate | 178 | $2,693 |
| Ranolazine ErRanolazine | 22 | $1,477 |
| Amiodarone Hcl | 52 | $1,152 |
| Losartan Potassium | 93 | $1,092 |
| Atorvastatin Calcium | 68 | $995 |
| Carvedilol | 48 | $733 |
| Rosuvastatin Calcium | 24 | $497 |
| Torsemide | 32 | $427 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 38 | $414 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $251 | $140,765127 claims |
| NovartisEntresto | $1,217 | $122,210118 claims |
| AstraZenecaBrilinta, Farxiga | $98 | $46,13545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Muskegon
- Varun YelamanchiliMuskegon$13K
- Thomas HillMuskegon$12K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.